Clinical Trials

90 enrolled

Endometrial Neoplasms

NCT03114527 2026-05-22

Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)

48 enrolled

Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma

NCT02321501 2026-05-20

Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer

37 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04195750 2026-05-14

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

755 enrolled 28 charts 1 FDA

Carcinoma, Renal Cell, Kidney Neoplasms

NCT01068249 2026-04-30

Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer

42 enrolled 11 charts

Recurrence, Endometrial Neoplasms

NCT03616587 2026-04-30

SERENA-1

396 enrolled

Breast Neoplasms

NCT05306340 2026-04-30

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

373 enrolled

Breast Neoplasms

NCT03049189 2026-04-06

COMPETE

324 enrolled 15 charts

EndocrineNET

Neuroendocrine Tumors

NCT02962414 2026-04-02

Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment

Phase 4 Active not recruiting

206 enrolled

Seizures, Tuberous Sclerosis

NCT05252585 2026-04-02

A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML)

4 enrolled

Tuberous Sclerosis, Angiomyolipoma

NCT00819546 2026-03-25

RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS

MyeloidOther hematologic neoplasm

29 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03950609 2026-03-19

Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors

36 enrolled

EndocrineNET

Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1

NCT05012371 2026-03-05

Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer

90 enrolled

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT02811861 2026-02-23

CLEAR

1,069 enrolled 12 charts 1 FDA

Carcinoma, Renal Cell

NCT02397083 2026-02-13

LEVER

102 enrolled

Endometrial Hyperplasia

NCT06105632 2026-02-13

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

333 enrolled

Breast Neoplasms, Recurrence

NCT02143726 2026-02-11

Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer

35 enrolled 14 charts

EndocrineHead & Neck

Thyroid cancer, Hurthle cell

NCT01674140 2026-02-10

e3

1,939 enrolled 15 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT01217931 2026-01-30

Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial

180 enrolled

Carcinoma, Renal Cell, Kidney Neoplasms

NCT02057133 2026-01-26

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

198 enrolled

Breast Neoplasms

NCT01087554 2026-01-16

Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer

249 enrolled

Advanced Cancer

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

24 enrolled

Breast Neoplasms

NCT03065387 2026-01-12

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

93 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT03740334 2025-11-21

Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL

LymphoidOther hematologic neoplasm

45 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01797523 2025-11-06

A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma

62 enrolled

Endometrial Neoplasms

NCT04185883 2025-10-22

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Other solid neoplasmSarcoma

610 enrolled

Advanced Solid Tumors

NCT04919226 2025-09-10

COMPOSE

EndocrineGastrointestinalNET

259 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT01141309 2025-07-22

Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer

41 enrolled

Head & Neck

Thyroid Diseases, Thyroid Neoplasms

NCT03032406 2025-07-22

CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer

53 enrolled 12 charts

Breast Neoplasms

NCT04188548 2025-06-04

EMBER

500 enrolled

BreastGynecologic

Breast Neoplasms, Endometrial Neoplasms

NCT01805271 2025-05-14

Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy

1,278 enrolled

Primary Non-metastatic Breast Cancer

NCT05293964 2024-11-29

Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer

214 enrolled

Breast Neoplasms

NCT04185831 2024-08-22

MEGALiT